![Paul Marinelli](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Marinelli
Direktor/Vorstandsmitglied bei
Neotx Holdings Ltd.
Vermögen: 272 750 $ am 31.08.2026
Profil
Paul T.
Marinelli is currently Director at Neotx Holdings Ltd. since 2020 and Director at Paramount Skydance Corp.
starting in 2025.
Formerly, Mr. Marinelli was Director-Corporate Development Group at Cadence Design Systems, Inc. in 2004, Independent Director at LeapFrog Enterprises, Inc. from 2011 to 2012, Director at Skydance Media LLC, Director at Autonomous Medical Devices, Inc., Director at Imagene AI Ltd., and Vice President at Lawrence Investments LLC from 2004 to 2015.
Education includes an MBA from Cornell University and an undergraduate degree from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0 % | 21.07.2026 | 25.000 ( 0 % ) | 272 750 $ | 31.08.2026 |
Aktive Positionen von Paul Marinelli
| Unternehmen | Position | Beginn |
|---|---|---|
Neotx Holdings Ltd.
 Neotx Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops oncology drugs | Direktor/Vorstandsmitglied | 20.02.2020 |
Ehemalige bekannte Positionen von Paul Marinelli
| Unternehmen | Position | Ende |
|---|---|---|
Lawrence Investments LLC
 Lawrence Investments LLC Real Estate Investment TrustsFinance Offers properties for sale via this unique venue | Corporate Officer/Principal | 01.01.2015 |
| CADENCE DESIGN SYSTEMS, INC. | Corporate Officer/Principal | 01.05.2004 |
Autonomous Medical Devices, Inc.
 Autonomous Medical Devices, Inc. Aerospace & DefenseElectronic Technology Develops micro biosensor, computer chips and diagnostic devices | Direktor/Vorstandsmitglied | - |
Imagene AI Ltd.
 Imagene AI Ltd. Information Technology ServicesTechnology Services Operates as AI-based molecular testing for cancer, leveraging the patient's histological data for personalized therapy | Direktor/Vorstandsmitglied | - |
Skydance Media LLC
 Skydance Media LLC Movies/EntertainmentConsumer Services Produces films and TV content | Direktor/Vorstandsmitglied | - |
Ausbildung von Paul Marinelli
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Cadence Design Systems, Inc.
 Cadence Design Systems, Inc. Packaged SoftwareTechnology Services Provides software services for semiconductor and electronics systems industries | Technology Services |
LeapFrog Enterprises, Inc.
 LeapFrog Enterprises, Inc. Recreational ProductsConsumer Durables Designs, develops and markets innovative technology-based learning platforms and related proprietary content for children | Consumer Durables |
Lawrence Investments LLC
Lawrence Investments LLC Real Estate Investment TrustsFinance Offers properties for sale via this unique venue | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Skydance Media LLC
Skydance Media LLC Movies/EntertainmentConsumer Services Produces films and TV content | Consumer Services |
Autonomous Medical Devices, Inc.
Autonomous Medical Devices, Inc. Aerospace & DefenseElectronic Technology Develops micro biosensor, computer chips and diagnostic devices | Electronic Technology |
Neotx Holdings Ltd.
Neotx Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops oncology drugs | Health Technology |
Imagene AI Ltd.
Imagene AI Ltd. Information Technology ServicesTechnology Services Operates as AI-based molecular testing for cancer, leveraging the patient's histological data for personalized therapy | Technology Services |
